acellular tissue engineered vessel
acellular tissue engineered vessel: 5 clinical trials tracked.
acellular tissue engineered vessel evidence translation
What we can confirm
5 tracked trials
What it means
What to watch
Prepared research question
What is verified about acellular tissue engineered vessel, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (5)
Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular Disease and Dialysis Access
A Prospective, Multi-center, Open-label Study, to Assess the Safety and Efficacy of SYMVESS® as a Vascular Conduit in Adolescents With Extremity Arterial Injury When Autologous Vein Graft is Not Feasible.
Primary endpoint: Number of Participants with Treatment-Related Adverse Events
A Phase 4 Observational Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real World Setting for Arterial Replacement or Reconstruction in Patients With Extremity Vascular Trauma
Primary endpoint: Kaplan-Meier estimated Symvess secondary patency
A Phase 3 Randomized Study to Compare the Efficacy and Safety of the Humacyte Acellular Tissue Engineered Vessel (ATEV) With That of an Autogenous Arteriovenous Fistula (AVF) in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
Primary endpoint: The number of catheter-free days since randomization to Month 12.
A Phase 2/3 Study for the Evaluation of Safety and Efficacy of Humacyte's ATEV for Vascular Replacement or Reconstruction in Patients With Life or Limb-threatening Vascular Trauma
Primary endpoint: Primary Patency Rate of the Human Acellular Vessel (HAV) at Day 30 in the All HAV Group